RU2013142364A - Замещенные производные 6,7-диалкокси-3-изохинолинола в качестве ингибиторов фосфодиэстеразы 10 (фдэ10а) - Google Patents
Замещенные производные 6,7-диалкокси-3-изохинолинола в качестве ингибиторов фосфодиэстеразы 10 (фдэ10а) Download PDFInfo
- Publication number
- RU2013142364A RU2013142364A RU2013142364/04A RU2013142364A RU2013142364A RU 2013142364 A RU2013142364 A RU 2013142364A RU 2013142364/04 A RU2013142364/04 A RU 2013142364/04A RU 2013142364 A RU2013142364 A RU 2013142364A RU 2013142364 A RU2013142364 A RU 2013142364A
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- dimethoxy
- dihydrochloride
- disorder
- group
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- -1 azido, hydroxy Chemical group 0.000 claims abstract 22
- 150000001875 compounds Chemical class 0.000 claims abstract 17
- 125000001424 substituent group Chemical group 0.000 claims abstract 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 10
- 125000003118 aryl group Chemical group 0.000 claims abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 6
- 125000005843 halogen group Chemical group 0.000 claims abstract 5
- 125000004104 aryloxy group Chemical group 0.000 claims abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000004171 alkoxy aryl group Chemical group 0.000 claims abstract 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract 3
- 125000004429 atom Chemical group 0.000 claims abstract 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 3
- 239000001257 hydrogen Substances 0.000 claims abstract 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims abstract 2
- 125000003277 amino group Chemical group 0.000 claims abstract 2
- 229910052799 carbon Inorganic materials 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 2
- 229910052736 halogen Inorganic materials 0.000 claims abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims abstract 2
- 208000028017 Psychotic disease Diseases 0.000 claims 21
- 206010012289 Dementia Diseases 0.000 claims 20
- 230000004770 neurodegeneration Effects 0.000 claims 18
- 208000020401 Depressive disease Diseases 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 230000001771 impaired effect Effects 0.000 claims 12
- 208000020925 Bipolar disease Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 9
- 208000024714 major depressive disease Diseases 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 201000000980 schizophrenia Diseases 0.000 claims 8
- 208000024254 Delusional disease Diseases 0.000 claims 7
- 208000018737 Parkinson disease Diseases 0.000 claims 7
- 208000014674 injury Diseases 0.000 claims 7
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 7
- 230000008733 trauma Effects 0.000 claims 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- 208000023105 Huntington disease Diseases 0.000 claims 6
- 206010007776 catatonia Diseases 0.000 claims 6
- 230000002490 cerebral effect Effects 0.000 claims 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 6
- 230000003533 narcotic effect Effects 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 4
- 206010034719 Personality change Diseases 0.000 claims 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 3
- GQSXXDNIECLFIW-UHFFFAOYSA-N 2H-isoquinolin-3-one dihydrochloride Chemical compound C1=CC2=CC(=O)NC=C2C=C1.Cl.Cl GQSXXDNIECLFIW-UHFFFAOYSA-N 0.000 claims 3
- 206010065040 AIDS dementia complex Diseases 0.000 claims 3
- 208000031091 Amnestic disease Diseases 0.000 claims 3
- 244000025254 Cannabis sativa Species 0.000 claims 3
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims 3
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims 3
- 206010010356 Congenital anomaly Diseases 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 3
- 206010012218 Delirium Diseases 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 208000013016 Hypoglycemia Diseases 0.000 claims 3
- 206010026749 Mania Diseases 0.000 claims 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims 3
- 101710138657 Neurotoxin Proteins 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 3
- 201000007737 Retinal degeneration Diseases 0.000 claims 3
- 208000020186 Schizophreniform disease Diseases 0.000 claims 3
- 229940025084 amphetamine Drugs 0.000 claims 3
- 206010008118 cerebral infarction Diseases 0.000 claims 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims 3
- 229960003920 cocaine Drugs 0.000 claims 3
- 208000026725 cyclothymic disease Diseases 0.000 claims 3
- 230000003001 depressive effect Effects 0.000 claims 3
- 208000024732 dysthymic disease Diseases 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 3
- 208000028329 epileptic seizure Diseases 0.000 claims 3
- 239000000380 hallucinogen Substances 0.000 claims 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims 3
- 230000035987 intoxication Effects 0.000 claims 3
- 231100000566 intoxication Toxicity 0.000 claims 3
- 238000007917 intracranial administration Methods 0.000 claims 3
- 239000002581 neurotoxin Substances 0.000 claims 3
- 231100000618 neurotoxin Toxicity 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 229940005483 opioid analgesics Drugs 0.000 claims 3
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims 3
- 229950010883 phencyclidine Drugs 0.000 claims 3
- 231100000572 poisoning Toxicity 0.000 claims 3
- 230000000607 poisoning effect Effects 0.000 claims 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 3
- 208000022610 schizoaffective disease Diseases 0.000 claims 3
- 239000003039 volatile agent Substances 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 claims 2
- 206010061216 Infarction Diseases 0.000 claims 2
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 230000007000 age related cognitive decline Effects 0.000 claims 2
- 125000005001 aminoaryl group Chemical group 0.000 claims 2
- 102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 claims 2
- 230000001505 hypomanic effect Effects 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000004258 retinal degeneration Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- MGRGSGSEPNEPJE-UHFFFAOYSA-N 1-ethyl-4-[[2-(ethylamino)-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxy-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCC)=C(O)N=C(CC)C2=C1 MGRGSGSEPNEPJE-UHFFFAOYSA-N 0.000 claims 1
- BTSKXFMPMDCFCA-UHFFFAOYSA-N 1-ethyl-4-[[2-(ethylamino)-7-fluoro-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxy-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=C(F)C=C4N=C3NCC)=C(O)N=C(CC)C2=C1 BTSKXFMPMDCFCA-UHFFFAOYSA-N 0.000 claims 1
- BGTMPYLBFUAQHC-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-(naphthalen-2-ylmethyl)-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC=C(C=CC=C2)C2=C1 BGTMPYLBFUAQHC-UHFFFAOYSA-N 0.000 claims 1
- DJJPQDXBFFRDNN-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-(quinolin-3-ylmethyl)-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CN=C(C=CC=C2)C2=C1 DJJPQDXBFFRDNN-UHFFFAOYSA-N 0.000 claims 1
- VBYLUENSVNFKPN-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[(2-methylquinolin-6-yl)methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC=C(N=C(C)C=C2)C2=C1 VBYLUENSVNFKPN-UHFFFAOYSA-N 0.000 claims 1
- ADIJDXVEENNLQW-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[(3-phenylphenyl)methyl]-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC(C=1)=CC=CC=1C1=CC=CC=C1 ADIJDXVEENNLQW-UHFFFAOYSA-N 0.000 claims 1
- HTODCQDAVFLCGE-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[(6-methoxyquinolin-3-yl)methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CN=C(C=CC(OC)=C2)C2=C1 HTODCQDAVFLCGE-UHFFFAOYSA-N 0.000 claims 1
- PLNFMLXCFNHUGV-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[(7-methoxyquinolin-3-yl)methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CN=C(C=C(OC)C=C2)C2=C1 PLNFMLXCFNHUGV-UHFFFAOYSA-N 0.000 claims 1
- OONPRRFULQGCFN-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[3-(4-methoxyphenyl)phenyl]methyl]-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC(C=1)=CC=CC=1C1=CC=C(OC)C=C1 OONPRRFULQGCFN-UHFFFAOYSA-N 0.000 claims 1
- NOIJZVSXLMQEJL-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[6-(methylamino)-[1,3]dioxolo[4,5-g]quinolin-7-yl]methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC(C(=NC1=C2)NC)=CC1=CC1=C2OCO1 NOIJZVSXLMQEJL-UHFFFAOYSA-N 0.000 claims 1
- IEQURDALEIJEIX-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[6-methoxy-2-(2-methoxyethylamino)quinolin-3-yl]methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCCOC IEQURDALEIJEIX-UHFFFAOYSA-N 0.000 claims 1
- HKWJSECIAGWHAV-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[6-methoxy-2-(methylamino)quinolin-3-yl]methyl]-2h-isoquinolin-3-one Chemical compound C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NC HKWJSECIAGWHAV-UHFFFAOYSA-N 0.000 claims 1
- FQRJDTOPZUNTSF-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[6-methoxy-2-(propan-2-ylamino)quinolin-3-yl]methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NC(C)C FQRJDTOPZUNTSF-UHFFFAOYSA-N 0.000 claims 1
- FBANUZRHSYFYSB-UHFFFAOYSA-N 1-ethyl-6,7-dimethoxy-4-[[6-methoxy-2-(propylamino)quinolin-3-yl]methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCCC)=C(O)N=C(CC)C2=C1 FBANUZRHSYFYSB-UHFFFAOYSA-N 0.000 claims 1
- HFVNDVLCVJBYIK-UHFFFAOYSA-N 3,6,7-trimethoxy-1-methyl-4-(naphthalen-2-ylmethyl)isoquinoline;hydrochloride Chemical compound Cl.C1=CC=CC2=CC(CC=3C(OC)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=C21 HFVNDVLCVJBYIK-UHFFFAOYSA-N 0.000 claims 1
- BSLRKZKLHQQATI-UHFFFAOYSA-N 4-(dibenzofuran-2-ylmethyl)-1-ethyl-6,7-dimethoxy-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC=C(OC=2C3=CC=CC=2)C3=C1 BSLRKZKLHQQATI-UHFFFAOYSA-N 0.000 claims 1
- FNMCICHSSNPOEH-UHFFFAOYSA-N 4-(dibenzofuran-2-ylmethyl)-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC=C(OC=2C3=CC=CC=2)C3=C1 FNMCICHSSNPOEH-UHFFFAOYSA-N 0.000 claims 1
- CTOHHRUHXXPTIZ-UHFFFAOYSA-N 4-(dibenzofuran-2-ylmethyl)-6,7-dimethoxy-1-propylisoquinolin-3-amine;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(N)=C1CC1=CC=C(OC=2C3=CC=CC=2)C3=C1 CTOHHRUHXXPTIZ-UHFFFAOYSA-N 0.000 claims 1
- FMSANJIVZDRHEG-UHFFFAOYSA-N 4-(isoquinolin-5-ylmethyl)-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one Chemical compound N1=CC=C2C(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=CC2=C1 FMSANJIVZDRHEG-UHFFFAOYSA-N 0.000 claims 1
- DVDXVRDJQQVUQP-UHFFFAOYSA-N 4-(isoquinolin-6-ylmethyl)-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C1=NC=CC2=CC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=C21 DVDXVRDJQQVUQP-UHFFFAOYSA-N 0.000 claims 1
- OSTDSZLKWVKGAL-UHFFFAOYSA-N 4-[(2-azido-6-methoxyquinolin-3-yl)methyl]-1-ethyl-6,7-dimethoxy-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1N=[N+]=[N-] OSTDSZLKWVKGAL-UHFFFAOYSA-N 0.000 claims 1
- LINJDHXBERWBQA-UHFFFAOYSA-N 4-[(2-butyl-6-methoxyquinolin-3-yl)methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3CCCC)=C(O)N=C(CCC)C2=C1 LINJDHXBERWBQA-UHFFFAOYSA-N 0.000 claims 1
- XTYBJTMZTAVKPZ-UHFFFAOYSA-N 4-[(2-ethyl-6-methoxyquinolin-3-yl)methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1CC XTYBJTMZTAVKPZ-UHFFFAOYSA-N 0.000 claims 1
- SZVUGARWWCBPPS-UHFFFAOYSA-N 4-[(3,4-dimethoxyphenyl)methyl]-3,6,7-trimethoxy-1-methylisoquinoline;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=C(OC)N=C(C)C2=CC(OC)=C(OC)C=C12 SZVUGARWWCBPPS-UHFFFAOYSA-N 0.000 claims 1
- ZMXLGFVWEKNIFA-UHFFFAOYSA-N 4-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=C(O)N=C(C)C2=CC(OC)=C(OC)C=C12 ZMXLGFVWEKNIFA-UHFFFAOYSA-N 0.000 claims 1
- KAGDIIFYXXVWJH-UHFFFAOYSA-N 4-[2-(ethylamino)-6-methoxyquinoline-3-carbonyl]-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(C(=O)C3=CC4=CC(OC)=CC=C4N=C3NCC)=C(O)N=C(C)C2=C1 KAGDIIFYXXVWJH-UHFFFAOYSA-N 0.000 claims 1
- FGFCTKRLUAPAEZ-UHFFFAOYSA-N 4-[[2-(benzylamino)-6-methoxyquinolin-3-yl]methyl]-1-ethyl-6,7-dimethoxy-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCC1=CC=CC=C1 FGFCTKRLUAPAEZ-UHFFFAOYSA-N 0.000 claims 1
- ZDCFYQHSRMELKU-UHFFFAOYSA-N 4-[[2-(dimethylamino)-6-methylquinolin-3-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(C)=CC=C2N=C1N(C)C ZDCFYQHSRMELKU-UHFFFAOYSA-N 0.000 claims 1
- YXQJQBZCXNFOKH-UHFFFAOYSA-N 4-[[2-(ethylamino)-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxy-1-(methoxymethyl)-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCC)=C(O)N=C(COC)C2=C1 YXQJQBZCXNFOKH-UHFFFAOYSA-N 0.000 claims 1
- BYNAPGZGYUBTOW-UHFFFAOYSA-N 4-[[2-(ethylamino)-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxy-1-propan-2-yl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCC)=C(O)N=C(C(C)C)C2=C1 BYNAPGZGYUBTOW-UHFFFAOYSA-N 0.000 claims 1
- JHIDGKNWYWURNG-UHFFFAOYSA-N 4-[[2-(ethylamino)-6-methylquinolin-3-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(C)=CC=C2N=C1NCC JHIDGKNWYWURNG-UHFFFAOYSA-N 0.000 claims 1
- ZWRMGTDJFIHXIG-UHFFFAOYSA-N 4-[[2-(ethylamino)-7-fluoro-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=C(F)C=C2N=C1NCC ZWRMGTDJFIHXIG-UHFFFAOYSA-N 0.000 claims 1
- XBCIZFMCIKUBPM-UHFFFAOYSA-N 4-[[3-(3-aminophenyl)phenyl]methyl]-1-ethyl-6,7-dimethoxy-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC(C=1)=CC=CC=1C1=CC=CC(N)=C1 XBCIZFMCIKUBPM-UHFFFAOYSA-N 0.000 claims 1
- SWBCIDGZDZCQKC-UHFFFAOYSA-N 4-[[6,7-dihydroxy-2-(methylamino)quinolin-3-yl]methyl]-6,7-dimethoxy-1-methyl-2H-isoquinolin-3-one dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(O)=C(O)C=C4N=C3NC)=C(O)N=C(C)C2=C1 SWBCIDGZDZCQKC-UHFFFAOYSA-N 0.000 claims 1
- KUCSXSVAROGQCH-UHFFFAOYSA-N 4-[[6-(dimethylamino)-[1,3]dioxolo[4,5-g]quinolin-7-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC(C(=NC1=C2)N(C)C)=CC1=CC1=C2OCO1 KUCSXSVAROGQCH-UHFFFAOYSA-N 0.000 claims 1
- VGFOROIFWFIFDX-UHFFFAOYSA-N 4-[[6-(ethylamino)-[1,3]dioxolo[4,5-g]quinolin-7-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC(C(=NC1=C2)NCC)=CC1=CC1=C2OCO1 VGFOROIFWFIFDX-UHFFFAOYSA-N 0.000 claims 1
- YZDNDYZIYOBDLJ-UHFFFAOYSA-N 4-[[6-ethoxy-2-(ethylamino)-7-fluoroquinolin-3-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OCC)=C(F)C=C2N=C1NCC YZDNDYZIYOBDLJ-UHFFFAOYSA-N 0.000 claims 1
- LZABEZCAFNVNPM-UHFFFAOYSA-N 4-[[6-ethoxy-2-(ethylamino)quinolin-3-yl]methyl]-1-ethyl-6,7-dimethoxy-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OCC)=CC=C4N=C3NCC)=C(O)N=C(CC)C2=C1 LZABEZCAFNVNPM-UHFFFAOYSA-N 0.000 claims 1
- YDOCMNYSXCPSGC-UHFFFAOYSA-N 4-[[6-ethoxy-2-(ethylamino)quinolin-3-yl]methyl]-6,7-dimethoxy-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OCC)=CC=C2N=C1NCC YDOCMNYSXCPSGC-UHFFFAOYSA-N 0.000 claims 1
- OBGRQVSZJGXHIY-UHFFFAOYSA-N 4-benzyl-6,7-dimethoxy-1-methyl-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC1=CC=CC=C1 OBGRQVSZJGXHIY-UHFFFAOYSA-N 0.000 claims 1
- VBLBHZVNNFZXJC-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-(naphthalen-2-ylmethyl)-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C1=CC=CC2=CC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CC=C21 VBLBHZVNNFZXJC-UHFFFAOYSA-N 0.000 claims 1
- JCQYYVCQQQMDBZ-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-(pyridin-4-ylmethyl)-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC1=CC=NC=C1 JCQYYVCQQQMDBZ-UHFFFAOYSA-N 0.000 claims 1
- HYUHVXKLZJJXCZ-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-(quinolin-3-ylmethyl)-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C1=CC=CC2=CC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CN=C21 HYUHVXKLZJJXCZ-UHFFFAOYSA-N 0.000 claims 1
- PQSLORMBUZTAIR-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[(3-phenoxyphenyl)methyl]-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC(C=1)=CC=CC=1OC1=CC=CC=C1 PQSLORMBUZTAIR-UHFFFAOYSA-N 0.000 claims 1
- FIEYUBKHKCVORP-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[(4-phenoxyphenyl)methyl]-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC(C=C1)=CC=C1OC1=CC=CC=C1 FIEYUBKHKCVORP-UHFFFAOYSA-N 0.000 claims 1
- NODLAOREKXDBOK-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[(5-phenylpyridin-3-yl)methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C=12C=C(OC)C(OC)=CC2=C(C)N=C(O)C=1CC(C=1)=CN=CC=1C1=CC=CC=C1 NODLAOREKXDBOK-UHFFFAOYSA-N 0.000 claims 1
- PZECIDJODGHFEA-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[[6-(methylamino)-[1,3]dioxolo[4,5-g]quinolin-7-yl]methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC=5OCOC=5C=C4N=C3NC)=C(O)N=C(C)C2=C1 PZECIDJODGHFEA-UHFFFAOYSA-N 0.000 claims 1
- DNXMINHITKWZHM-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-4-[[6-methyl-2-(methylamino)quinolin-3-yl]methyl]-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(C)=CC=C4N=C3NC)=C(O)N=C(C)C2=C1 DNXMINHITKWZHM-UHFFFAOYSA-N 0.000 claims 1
- KBYPBHQYLMZWOF-UHFFFAOYSA-N 6,7-dimethoxy-1-propyl-4-(quinolin-3-ylmethyl)-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CN=C(C=CC=C2)C2=C1 KBYPBHQYLMZWOF-UHFFFAOYSA-N 0.000 claims 1
- DAKABUXELXLYOR-UHFFFAOYSA-N 6,7-dimethoxy-4-(naphthalen-2-ylmethyl)-1-propyl-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC=C(C=CC=C2)C2=C1 DAKABUXELXLYOR-UHFFFAOYSA-N 0.000 claims 1
- OEIKCOFHXZCRTE-UHFFFAOYSA-N 6,7-dimethoxy-4-[(2-methylquinolin-6-yl)methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC=C(N=C(C)C=C2)C2=C1 OEIKCOFHXZCRTE-UHFFFAOYSA-N 0.000 claims 1
- ZHSSSQRURJOYPA-UHFFFAOYSA-N 6,7-dimethoxy-4-[(5-methoxyquinolin-3-yl)methyl]-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C1=CC=C(OC)C2=CC(CC=3C(O)=NC(C)=C4C=C(C(=CC4=3)OC)OC)=CN=C21 ZHSSSQRURJOYPA-UHFFFAOYSA-N 0.000 claims 1
- GVNGURGDKRZERV-UHFFFAOYSA-N 6,7-dimethoxy-4-[(6-methoxyquinolin-3-yl)methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CN=C(C=CC(OC)=C2)C2=C1 GVNGURGDKRZERV-UHFFFAOYSA-N 0.000 claims 1
- GZQFKZILSHRCLQ-UHFFFAOYSA-N 6,7-dimethoxy-4-[(7-methoxyquinolin-3-yl)methyl]-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC=C(C=C4N=C3)OC)=C(O)N=C(C)C2=C1 GZQFKZILSHRCLQ-UHFFFAOYSA-N 0.000 claims 1
- FRQGPQPHXBSQPB-UHFFFAOYSA-N 6,7-dimethoxy-4-[(7-methoxyquinolin-3-yl)methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CN=C(C=C(OC)C=C2)C2=C1 FRQGPQPHXBSQPB-UHFFFAOYSA-N 0.000 claims 1
- AISBYBQYHDJIOJ-UHFFFAOYSA-N 6,7-dimethoxy-4-[[5-(4-methoxyphenyl)pyridin-3-yl]methyl]-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1C1=CN=CC(CC=2C3=CC(OC)=C(OC)C=C3C(C)=NC=2O)=C1 AISBYBQYHDJIOJ-UHFFFAOYSA-N 0.000 claims 1
- QRBAUUCYXVMNPO-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-(4-methoxyphenyl)pyridin-2-yl]methyl]-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C1=CC(OC)=CC=C1C1=CC=CC(CC=2C3=CC(OC)=C(OC)C=C3C(C)=NC=2O)=N1 QRBAUUCYXVMNPO-UHFFFAOYSA-N 0.000 claims 1
- DHJAWBRYBVKAKG-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-(methylamino)-[1,3]dioxolo[4,5-g]quinolin-7-yl]methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC(C(=NC1=C2)NC)=CC1=CC1=C2OCO1 DHJAWBRYBVKAKG-UHFFFAOYSA-N 0.000 claims 1
- GWENWLLTWAKHQN-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(2,2,2-trifluoroethylamino)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCC(F)(F)F GWENWLLTWAKHQN-UHFFFAOYSA-N 0.000 claims 1
- MPAYZJKTQWPELV-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(2-methoxyethylamino)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCCOC MPAYZJKTQWPELV-UHFFFAOYSA-N 0.000 claims 1
- KUNTZLSIGITAIM-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(methylamino)quinolin-3-yl]methyl]-1-methyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NC)=C(O)N=C(C)C2=C1 KUNTZLSIGITAIM-UHFFFAOYSA-N 0.000 claims 1
- MHURYTZHRWHSAM-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(methylamino)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NC MHURYTZHRWHSAM-UHFFFAOYSA-N 0.000 claims 1
- JJHGVTORLVSJBS-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(propan-2-ylamino)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NC(C)C JJHGVTORLVSJBS-UHFFFAOYSA-N 0.000 claims 1
- RHWRUUIHGOVMGV-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(propylamino)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCCC)=C(O)N=C(CCC)C2=C1 RHWRUUIHGOVMGV-UHFFFAOYSA-N 0.000 claims 1
- MINOHQQVIKZUBZ-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methoxy-2-(trifluoromethyl)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one;hydrochloride Chemical compound Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1C(F)(F)F MINOHQQVIKZUBZ-UHFFFAOYSA-N 0.000 claims 1
- ZOTRUCVXAQRWTN-UHFFFAOYSA-N 6,7-dimethoxy-4-[[6-methyl-2-(methylamino)quinolin-3-yl]methyl]-1-propyl-2h-isoquinolin-3-one;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(C)=CC=C2N=C1NC ZOTRUCVXAQRWTN-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 206010056997 Impaired fasting glucose Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 208000034461 Progressive cone dystrophy Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000016624 Retinal neoplasm Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 208000027073 Stargardt disease Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- GNAZSOBKJRSETJ-UHFFFAOYSA-N [1-(acetamidomethyl)-4-[[2-(ethylamino)-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxyisoquinolin-3-yl] acetate Chemical compound COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCC)=C(OC(C)=O)N=C(CNC(C)=O)C2=C1 GNAZSOBKJRSETJ-UHFFFAOYSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 201000008615 cone dystrophy Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000011325 dry age related macular degeneration Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 231100000567 intoxicating Toxicity 0.000 claims 1
- 230000002673 intoxicating effect Effects 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- QXXDTQJIPIKKGF-UHFFFAOYSA-N methanesulfonamide;dihydrochloride Chemical compound Cl.Cl.CS(N)(=O)=O QXXDTQJIPIKKGF-UHFFFAOYSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- NCDVSIWWXGWTKU-UHFFFAOYSA-N n-[2-[[3-[(1-ethyl-6,7-dimethoxy-3-oxo-2h-isoquinolin-4-yl)methyl]-6-methoxyquinolin-2-yl]amino]ethyl]acetamide;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCCNC(C)=O NCDVSIWWXGWTKU-UHFFFAOYSA-N 0.000 claims 1
- RXQOVSGSVHFVNW-UHFFFAOYSA-N n-[2-[[3-[(6,7-dimethoxy-1-methyl-3-oxo-2h-isoquinolin-4-yl)methyl]-6-methoxyquinolin-2-yl]amino]ethyl]acetamide;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC=3C(NCCNC(C)=O)=NC4=CC=C(C=C4C=3)OC)=C(O)N=C(C)C2=C1 RXQOVSGSVHFVNW-UHFFFAOYSA-N 0.000 claims 1
- VSRPFDAROAUHNM-UHFFFAOYSA-N n-[2-[[3-[(6,7-dimethoxy-3-oxo-1-propyl-2h-isoquinolin-4-yl)methyl]-6-ethoxyquinolin-2-yl]amino]ethyl]acetamide;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OCC)=CC=C2N=C1NCCNC(C)=O VSRPFDAROAUHNM-UHFFFAOYSA-N 0.000 claims 1
- DOPLUZLCSSWCKY-UHFFFAOYSA-N n-[2-[[3-[(6,7-dimethoxy-3-oxo-1-propyl-2h-isoquinolin-4-yl)methyl]-6-methoxyquinolin-2-yl]amino]ethyl]acetamide;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC1=CC2=CC(OC)=CC=C2N=C1NCCNC(C)=O DOPLUZLCSSWCKY-UHFFFAOYSA-N 0.000 claims 1
- PNPHYPDGACNKKG-UHFFFAOYSA-N n-[2-[[6-(cyclopropylmethoxy)-3-[(1-ethyl-6,7-dimethoxy-3-oxo-2h-isoquinolin-4-yl)methyl]quinolin-2-yl]amino]ethyl]acetamide;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CC)=NC(O)=C1CC(C(=NC1=CC=2)NCCNC(C)=O)=CC1=CC=2OCC1CC1 PNPHYPDGACNKKG-UHFFFAOYSA-N 0.000 claims 1
- KWOBCKDHUOUKGR-UHFFFAOYSA-N n-[2-[[6-(cyclopropylmethoxy)-3-[(6,7-dimethoxy-3-oxo-1-propyl-2h-isoquinolin-4-yl)methyl]quinolin-2-yl]amino]ethyl]acetamide;dihydrochloride Chemical compound Cl.Cl.C12=CC(OC)=C(OC)C=C2C(CCC)=NC(O)=C1CC(C(=NC1=CC=2)NCCNC(C)=O)=CC1=CC=2OCC1CC1 KWOBCKDHUOUKGR-UHFFFAOYSA-N 0.000 claims 1
- DXEBICMERHGPMP-UHFFFAOYSA-N n-[[4-[[2-(ethylamino)-6-methoxyquinolin-3-yl]methyl]-6,7-dimethoxy-3-oxo-2h-isoquinolin-1-yl]methyl]acetamide;dihydrochloride Chemical compound Cl.Cl.COC1=C(OC)C=C2C(CC3=CC4=CC(OC)=CC=C4N=C3NCC)=C(O)N=C(CNC(C)=O)C2=C1 DXEBICMERHGPMP-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 239000000790 retinal pigment Substances 0.000 claims 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161444566P | 2011-02-18 | 2011-02-18 | |
| US61/444,566 | 2011-02-18 | ||
| PCT/US2012/025731 WO2012112946A1 (en) | 2011-02-18 | 2012-02-17 | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013142364A true RU2013142364A (ru) | 2015-03-27 |
Family
ID=45787353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013142364/04A RU2013142364A (ru) | 2011-02-18 | 2012-02-17 | Замещенные производные 6,7-диалкокси-3-изохинолинола в качестве ингибиторов фосфодиэстеразы 10 (фдэ10а) |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8772316B2 (https=) |
| EP (1) | EP2675791B1 (https=) |
| JP (1) | JP2014510055A (https=) |
| KR (1) | KR20140009372A (https=) |
| CN (1) | CN103476757A (https=) |
| AU (1) | AU2012219316A1 (https=) |
| BR (1) | BR112013021180A2 (https=) |
| CA (1) | CA2827724A1 (https=) |
| CL (1) | CL2013002394A1 (https=) |
| IL (1) | IL228008A0 (https=) |
| MX (1) | MX2013009575A (https=) |
| RU (1) | RU2013142364A (https=) |
| SG (1) | SG192839A1 (https=) |
| WO (1) | WO2012112946A1 (https=) |
| ZA (1) | ZA201306416B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2827724A1 (en) | 2011-02-18 | 2012-08-23 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| JP6272604B2 (ja) * | 2013-12-27 | 2018-01-31 | 日本サプリメント株式会社 | 糖取り込み促進剤 |
| CN104370813A (zh) * | 2014-10-22 | 2015-02-25 | 上海大学 | 异喹啉-6-甲醛的制备方法 |
| SG11201806416XA (en) | 2016-02-12 | 2018-08-30 | Astellas Pharma Inc | Tetrahydroisoquinoline derivatives |
| BR112019010511A2 (pt) | 2016-11-23 | 2019-09-17 | Bayer Ag | derivados de heterociclo bicíclico fundido como pesticidas |
| US12234217B2 (en) | 2018-12-03 | 2025-02-25 | Fmc Corporation | Method for preparing N-phenylpyrazole-1-carboxamides |
| CN113376287A (zh) * | 2021-06-15 | 2021-09-10 | 劲牌有限公司 | 基于高效液相色谱法检测环核苷酸磷酸二酯酶抑制剂活性的方法 |
| PY2501648A (es) | 2024-01-12 | 2025-10-31 | Syngenta Crop Protection Ag | Nuevos compuestos de carboxamida |
| WO2026008750A1 (en) | 2024-07-05 | 2026-01-08 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| GB0008694D0 (en) * | 2000-04-07 | 2000-05-31 | Novartis Ag | Organic compounds |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| DE10130167A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
| WO2003014116A1 (en) | 2001-08-06 | 2003-02-20 | Bayer Corporation | Pyrrolo[2.1-a]isoquinoline derivatives |
| US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
| WO2004002484A1 (ja) | 2002-06-26 | 2004-01-08 | Kyowa Hakko Kogyo Co., Ltd. | ホスホジエステラーゼ阻害剤 |
| DE10230604A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
| DE10230605A1 (de) | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
| US20070105840A1 (en) | 2003-06-30 | 2007-05-10 | Altana Pharma Ag | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| RS20050945A (sr) | 2003-06-30 | 2008-06-05 | Altana Pharma Ag., | Novi pirolodihidroizohinolini koji se mogu upotrebiti u tretmanu kancera |
| EP1651251A4 (en) | 2003-07-31 | 2008-06-18 | Bayer Pharmaceuticals Corp | METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS |
| EP1723134A2 (en) | 2004-02-18 | 2006-11-22 | Pfizer Products Incorporated | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline |
| EP1755611A1 (en) | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| US20060019975A1 (en) | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| CA2578996A1 (en) | 2004-09-03 | 2006-03-16 | Memory Pharmaceuticals Corporation | 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| WO2006034491A2 (en) | 2004-09-23 | 2006-03-30 | Bayer Pharmaceuticals Corporation | Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes |
| US7576080B2 (en) | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
| US20060183763A1 (en) | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| KR100896380B1 (ko) | 2005-01-07 | 2009-05-08 | 화이자 프로덕츠 인코포레이티드 | 헤테로방향족 퀴놀린 화합물 및 ｐｄｅ10 저해제로서의그의 용도 |
| AU2006218054A1 (en) | 2005-01-12 | 2006-08-31 | Nycomed Gmbh | Novel pyrrolodihydroisoquinolines as PDE10 inhibitors |
| CA2595075A1 (en) | 2005-01-12 | 2006-07-20 | Matthias Vennemann | Pyrrolodihydroisoquinolines as antiproliferative agents |
| MX2008002207A (es) | 2005-08-16 | 2008-03-27 | Memory Pharm Corp | Inhibidores de fosfodiesterasa 10. |
| JP2009524637A (ja) | 2006-01-27 | 2009-07-02 | ファイザー・プロダクツ・インク | アミノフタラジン誘導体化合物 |
| CA2643963A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| WO2007098214A1 (en) | 2006-02-21 | 2007-08-30 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| WO2007096743A1 (en) | 2006-02-23 | 2007-08-30 | Pfizer Products Inc. | Substituted quinazolines as pde10 inhibitors |
| US20070287707A1 (en) | 2006-02-28 | 2007-12-13 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| US20090099175A1 (en) | 2006-03-01 | 2009-04-16 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
| WO2007103554A1 (en) | 2006-03-08 | 2007-09-13 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| ES2392553T3 (es) * | 2006-07-10 | 2012-12-11 | H. Lundbeck A/S | Derivados (3-aril-piperazina-1-ilo) de 6,7-dialcoxiquinazolina, 6,7-dialcoxiftalazina y 6,7-dialcoxiisoquinolina |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| CA2663178C (en) | 2006-09-11 | 2016-01-12 | Matrix Laboratories Ltd. | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
| CN101166128A (zh) | 2006-10-16 | 2008-04-23 | 琥珀技术有限公司 | 一种提供第三方服务的方法及相应的系统 |
| US7786139B2 (en) | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| EP2083819B1 (en) | 2006-11-21 | 2017-02-22 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| US20090062277A1 (en) | 2007-08-21 | 2009-03-05 | Essa Hu | Phosphodiesterase 10 inhibitors |
| WO2009025839A2 (en) | 2007-08-22 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| US20090054434A1 (en) | 2007-08-23 | 2009-02-26 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| TW200918519A (en) | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
| EP2227472A1 (en) | 2007-11-30 | 2010-09-15 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| US20090143361A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| KR20100110804A (ko) | 2007-11-30 | 2010-10-13 | 와이어쓰 엘엘씨 | 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진 |
| WO2009143178A2 (en) | 2008-05-20 | 2009-11-26 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| US8133897B2 (en) | 2008-06-20 | 2012-03-13 | H. Lundbeck A/S | Phenylimidazole derivatives as PDE10A enzyme inhibitors |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| JP2011526294A (ja) | 2008-06-25 | 2011-10-06 | エンビボ ファーマシューティカルズ インコーポレイテッド | ホスホジエステラーゼ１０阻害剤としての二置換フェニル化合物 |
| BRPI0914772A2 (pt) | 2008-06-25 | 2015-10-20 | Envivo Pharmaceuticals Inc | compostos heterocíclicos 1,2-dissubstituídos |
| EP2318410A2 (en) | 2008-07-09 | 2011-05-11 | Envivo Pharmaceuticals, Inc. | New small-molecule pde-10 inhibitors |
| AU2009279756B2 (en) | 2008-08-05 | 2015-01-29 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| MX2011002399A (es) | 2008-09-04 | 2011-04-07 | Mitsubishi Tanabe Pharma Corp | Compuestos pirimidina tri-sustituida y su uso como inhibidores de fosfodiesterasa 10. |
| CA2741303A1 (en) | 2008-10-28 | 2010-06-03 | Schering Corporation | Substituted pyrazoloquinolines and derivatives thereof |
| WO2010054260A1 (en) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
| WO2010054253A1 (en) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Triazine derivatives as inhibitors of phosphodiesterases |
| TW201030001A (en) | 2008-11-14 | 2010-08-16 | Amgen Inc | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors |
| SG171954A1 (en) | 2008-12-04 | 2011-07-28 | Hoffmann La Roche | Pyridazinone derivatives |
| ES2397934T3 (es) | 2008-12-17 | 2013-03-12 | Amgen Inc. | Compuestos de aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10 |
| AU2010211050B2 (en) | 2009-02-05 | 2016-05-12 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds |
| US9187455B2 (en) | 2009-02-23 | 2015-11-17 | Hoffmann-La Roche Inc. | Substituted pyridazines as PDE10A inhibitors |
| EP2400991A1 (en) | 2009-02-24 | 2012-01-04 | Janssen Pharmaceutica, N.V. | Radiolabelled pde10 ligands |
| US8685967B2 (en) | 2009-04-07 | 2014-04-01 | Merck Sharp & Dohme Corp. | Substituted triazolopyridines and analogs thereof |
| CN105125547A (zh) | 2009-05-07 | 2015-12-09 | 费瑞姆医药有限公司 | 苯氧基甲基杂环化合物 |
| EP2434885B1 (en) | 2009-05-27 | 2014-03-26 | Merck Sharp & Dohme Corp. | Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors |
| AU2010254149B2 (en) | 2009-05-29 | 2014-08-21 | Merck Sharp & Dohme Llc | Radiolabeled PDE10 inhibitors |
| WO2010138585A1 (en) | 2009-05-29 | 2010-12-02 | Merck Sharp & Dohme Corp. | Pyrimidinones as pde10 inhibitors |
| TW201111383A (en) | 2009-05-29 | 2011-04-01 | Wyeth Llc | Substituted imidazo[1,5-a]quinoxalines as inhibitors of phosphodiesterase 10 |
| CA2765750A1 (en) | 2009-06-19 | 2010-12-23 | H. Lundbeck A/S | Novel phenylimidazole derivative as pde10a enzyme inhibitor |
| EP2467382B1 (en) | 2009-08-17 | 2014-06-25 | Merck Sharp & Dohme Corp. | Amino tetrahydro-pyridopyrimidine pde10 inhibitors |
| PE20121438A1 (es) | 2009-09-24 | 2012-10-26 | Hoffmann La Roche | Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a |
| WO2011053559A1 (en) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Aryl aminopyridine pde10 inhibitors |
| KR101774035B1 (ko) | 2009-10-30 | 2017-09-01 | 얀센 파마슈티카 엔.브이. | 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도 |
| AU2010311493B2 (en) | 2009-10-30 | 2014-06-05 | Janssen Pharmaceutica Nv | Radiolabelled PDE10 ligands |
| TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| TWI487705B (zh) | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物 |
| TW201200516A (en) | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
| US8470820B2 (en) | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
| ES2540867T3 (es) | 2010-02-26 | 2015-07-14 | Mitsubishi Tanabe Pharma Corporation | Compuestos de pirazolopirimidina y su uso como inhibidores de PDE10 |
| JP2011201873A (ja) | 2010-03-03 | 2011-10-13 | Mitsubishi Tanabe Pharma Corp | 三置換ピリミジン化合物及びそのｐｄｅ１０阻害薬としての使用 |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| KR101713453B1 (ko) | 2010-03-12 | 2017-03-07 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
| US8410117B2 (en) | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
| WO2011132048A1 (en) | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceutical S.A. | Heteroaryl compounds as pde10a inhibitors |
| WO2011132051A2 (en) | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Tricycle compounds as phosphodiesterase-10 inhibitors |
| WO2011138657A1 (en) | 2010-05-04 | 2011-11-10 | Glenmark Pharmaceuticals S.A. | Aryl substituted olefinic compounds as pde10a inhibitors |
| JP2013526546A (ja) | 2010-05-13 | 2013-06-24 | アムジエン・インコーポレーテツド | Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物 |
| AU2011253058A1 (en) | 2010-05-13 | 2012-12-06 | Amgen Inc. | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors |
| WO2011143365A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| US8969349B2 (en) | 2010-05-26 | 2015-03-03 | Sunovion Pharmaceuticals Inc. | Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors |
| US8703768B2 (en) | 2010-06-09 | 2014-04-22 | Hoffmann-La Roche Inc. | Nitrogen containing heteroaryl compounds |
| WO2011163355A1 (en) | 2010-06-24 | 2011-12-29 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors |
| TW201215607A (en) | 2010-07-02 | 2012-04-16 | Lundbeck & Co As H | Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor |
| TW201206935A (en) | 2010-07-16 | 2012-02-16 | Lundbeck & Co As H | Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor |
| CA2827724A1 (en) | 2011-02-18 | 2012-08-23 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US9200016B2 (en) * | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
-
2012
- 2012-02-17 CA CA2827724A patent/CA2827724A1/en not_active Abandoned
- 2012-02-17 KR KR1020137024525A patent/KR20140009372A/ko not_active Withdrawn
- 2012-02-17 EP EP12706983.9A patent/EP2675791B1/en not_active Not-in-force
- 2012-02-17 SG SG2013062807A patent/SG192839A1/en unknown
- 2012-02-17 MX MX2013009575A patent/MX2013009575A/es not_active Application Discontinuation
- 2012-02-17 US US13/399,351 patent/US8772316B2/en active Active
- 2012-02-17 AU AU2012219316A patent/AU2012219316A1/en not_active Abandoned
- 2012-02-17 BR BR112013021180A patent/BR112013021180A2/pt not_active IP Right Cessation
- 2012-02-17 CN CN2012800184663A patent/CN103476757A/zh active Pending
- 2012-02-17 RU RU2013142364/04A patent/RU2013142364A/ru not_active Application Discontinuation
- 2012-02-17 WO PCT/US2012/025731 patent/WO2012112946A1/en not_active Ceased
- 2012-02-17 JP JP2013554657A patent/JP2014510055A/ja active Pending
-
2013
- 2013-08-18 IL IL228008A patent/IL228008A0/en unknown
- 2013-08-19 CL CL2013002394A patent/CL2013002394A1/es unknown
- 2013-08-26 ZA ZA2013/06416A patent/ZA201306416B/en unknown
-
2014
- 2014-06-25 US US14/314,930 patent/US9670181B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20120214837A1 (en) | 2012-08-23 |
| US8772316B2 (en) | 2014-07-08 |
| BR112013021180A2 (pt) | 2019-09-24 |
| KR20140009372A (ko) | 2014-01-22 |
| ZA201306416B (en) | 2014-04-30 |
| US20140309253A1 (en) | 2014-10-16 |
| EP2675791A1 (en) | 2013-12-25 |
| CL2013002394A1 (es) | 2014-07-04 |
| US9670181B2 (en) | 2017-06-06 |
| CN103476757A (zh) | 2013-12-25 |
| EP2675791B1 (en) | 2016-02-17 |
| IL228008A0 (en) | 2013-09-30 |
| JP2014510055A (ja) | 2014-04-24 |
| MX2013009575A (es) | 2014-10-14 |
| SG192839A1 (en) | 2013-09-30 |
| CA2827724A1 (en) | 2012-08-23 |
| AU2012219316A1 (en) | 2013-10-03 |
| WO2012112946A1 (en) | 2012-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013142364A (ru) | Замещенные производные 6,7-диалкокси-3-изохинолинола в качестве ингибиторов фосфодиэстеразы 10 (фдэ10а) | |
| JP2014510055A5 (https=) | ||
| JP2022533912A5 (https=) | ||
| JP2013544277A5 (https=) | ||
| NZ598781A (en) | Compounds as tyrosine kinase modulators | |
| JP2011526294A5 (https=) | ||
| RU2016131875A (ru) | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы | |
| JP2013503903A5 (https=) | ||
| JP2014507455A5 (https=) | ||
| EA201001696A1 (ru) | СОЕДИНЕНИЯ ХИНУКЛИДИНА В КАЧЕСТВЕ ЛИГАНДОВ НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА α7 | |
| JP2016501189A5 (https=) | ||
| RU2015137619A (ru) | Замещенные нафтиридиновые и хинолиновые соединения как ингибиторы мао | |
| JP2021518844A5 (https=) | ||
| JP7383598B2 (ja) | Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤 | |
| JP2013533253A5 (https=) | ||
| JP2015516429A5 (https=) | ||
| JP2016531126A5 (https=) | ||
| CN111511745A (zh) | 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用 | |
| JP2020506895A5 (https=) | ||
| JP2010525024A5 (https=) | ||
| JP2012532125A5 (https=) | ||
| JP2018536685A5 (https=) | ||
| MX2016013968A (es) | Compuestos heteroaromaticos y su uso como ligandos de dopamina d1. | |
| JP2024160326A (ja) | Ｅａａｔ２活性化因子およびその使用方法 | |
| MA39914A (fr) | Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20150218 |